1 active not recruiting, 1 not yet recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Unresectable Esophageal Squamous Cell Carcinoma: new trials by email Literature Review of Unresectable Esophageal Squamous Cell Carcinoma trials Research Report on Unresectable Esophageal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma. Concurrent chemoradiotherapy (cCRT), Induced treatment - Advanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 50 | 2026-03-10 | 2026-03-13 |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Home Health Encounter, Nivolumab, Patient Monitoring - Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 50 | 2024-04-30 | 2026-10-02 |
| AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC AK104, Cisplatin, Paclitaxel - Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 80 | 2022-10-01 | 2022-08-31 |
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Adavosertib, Radiation Therapy - Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 4 | 2021-04-09 | 2026-07-31 |
Esophageal Squamous Cell Carcinoma (3) · Adenocarcinoma Of Esophagus (1) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Melanoma (1) · Meningeal Carcinomatosis (1) · Squamous Cell Carcinoma of Head and Neck (1)
Carcinoma (3) · Carcinoma, Squamous Cell (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Esophageal Diseases (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Head and Neck Neoplasms (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Squamous Cell (3) · Esophageal Neoplasms (2) · Adenocarcinoma (1)
Chemoradiotherapy (1) · Cisplatin (1) · Home Care Services (1) · House Calls (1) · Nivolumab (1) · Paclitaxel (1) · Radiation (1) · Radiotherapy (1) · Remote Patient Monitoring (1) · adavosertib (1)
Chinese Academy of Medical Sciences (1) · Fudan University (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1)
United States (2)
Eric D Miller (1) · Jing Huang, M.D. (1) · Roxana S. Dronca, M.D. (1)
UM1CA186712 (1)